American Diabetes Association’s Post

We welcome the ADA’s guidance against unapproved compounded medicines, which rightly points out the “uncertainty about their content, safety, quality, and effectiveness.” No patient should be exposed to unapproved knockoff drugs with heightened risks, particularly when safe and effective FDA-approved medicines are available. Mass-produced unapproved drugs may expose patients to potentially life-threatening risks. Patient safety remains Lilly's top concern, but our efforts alone are not enough. We appreciate the ADA’s continued commitment to patient safety.

In recent years, GLP-1 receptor agonists have become vital tools for managing type 2 diabetes and obesity. Their growing popularity, however, has led to increased demand, product shortages, and the rise of compounded alternatives. While compounded GLP-1 formulations may appear to offer affordable solutions, they come with serious risks, including concerns around dosing accuracy, potential counterfeit products, and lack of FDA regulation. As highlighted in the American Diabetes Association's recent statement, compounded versions bypass critical safety measures—posing dangers for patients who are not closely monitored by healthcare professionals. In a recent blog, we explore the importance of close monitoring when patients use GLP-1 medications. For insulin pump users, the stakes are even higher, as any variability in medication safety or efficacy can have significant consequences for blood glucose management. Ultimately, ensuring access to regulated, FDA-approved medications is essential for optimal outcomes in diabetes care. 🔗 Find more in our blog here: https://lnkd.in/gCxANB_e

The FDA has recently cleared a new insulin patch pump by embecta that was developed with the needs of people with type 2 diabetes in mind. And a key feature of the patch pump is its 300-unit reservoir for people who have higher daily insulin needs! Here’s an overview of the embecta patch pump and what you can expect once the patch pump becomes available >> bit.ly/47YuB8H #myAMCR #HeadlandsResearchAMCR #Type2Diabetes #DiabetesManagement #InsulinPump #InsulinPumpTherapy #DiabetesTreatment

The FDA has approved the first generic once-daily GLP-1 injection, liraglutide, for type 2 diabetes. This milestone aims to make diabetes treatment more accessible and affordable. Liraglutide helps regulate blood sugar and can aid in weight loss. This approval is a significant step towards better diabetes management. #FDA #Diabetes #Healthcare #GLP1 #Liraglutide #MedicalNews You can read more about it here: https://lnkd.in/exTzqYNG

Announcement: 📣 An important update to PBS subsidised #T2D medications only just published over the weekend. Table 2 (below) makes the current paradigm very clear. You can't start a PBS-subsidised GLP-1RA (Ozempic/Trulicity) for #diabetes unless you've tried and found a SGLT2i to be insufficiently effective or not tolerated. GLP-1RAs are now a telephone/electronic authority and *no longer a streamlined code entry for the first prescription* Importantly, you can prescribe a PBS-subsidised GLP-1RA and SGLT2i together if the GLP-1RA is for diabetes but the SGLT2i is not (E.g. CKD or CHF). These changes aim to reduce the demand for GLP1RAs by ensuring that a SGLT2i is trialled first for glycaemic control, and for a private script to be utilised for weight-loss purposes (E.g. Saxenda); improving access to GLP1RAs for people living with Type 2 Diabetes. Article: https://lnkd.in/gddB2U6R. Table: https://lnkd.in/gjGnutTR

Do you think, the prescribing of insulin for person's living with Type 2 diabetes (PLwT2D) means "Their Diabetes" has gone from bad to worse? The common thought trend for most PLwT2D, who were previously managed with oral diabetes medicines, and are now told they have to switch to insulin or combine insulin with oral medicines is; "MY DIABETES HAS GONE FROM BAD TO WORSE". Do you agree with this thought trend? How can convince person's with this thought trend otherwise? #truthbynkiru #tdcdiabetescommunity #diabeteseducation #diabetesadvocacy NB: Please visit my YouTube channel, like, subscribe and turn on the notification button. https://lnkd.in/eDBnMRcZ

Explore the pros and cons of GLP-1 medications for managing type 2 diabetes and weight loss. This article delves into the high costs of brand-name drugs like Ozempic and Trulicity, the appeal of cheaper compounded alternatives, and the significant risks associated with compounded medications. Discover safer strategies for managing treatment costs without compromising safety or efficacy. Read more here ➡️: https://lnkd.in/gBXNGaEr #GLP1 #WeightLoss #Diabetes

🌟 Tria Triumph: GLP-1’s are Not for Everyone! 🌟 A patient with diabetes and a history of a heart attack initially faced GI discomfort from metformin IR. After a change in medication to Ozempic, their GI symptoms worsened dramatically. The patient described the issues as “wicked” with severe gas, nausea, and diarrhea. Our Tria Health pharmacist stepped in, thoroughly investigating the timeline of symptoms and medication changes. By pinpointing Ozempic as the likely cause, the pharmacist recommended discontinuing it and returning to metformin, this time in the extended-release (ER) formulation. Today, the patient’s HgbA1C and blood glucose levels are at goal, thanks to careful medication management and personalized care. This case highlights the power of attentive pharmaceutical care in achieving optimal health outcomes. #GLP1 #PersonalizedCare #MedicationManagement

One shot, all week long! Explore the future of diabetes care with once-weekly basal insulins 1️⃣ 👏 👀 👉: Dive into the latest scoop on Novo Nordisk's weekly basal insulin awaiting FDA verdict. Are we on the brink of a revolution in diabetes management? Get the inside scoop now! READ NOW- https://bit.ly/4cJQ4nI #TCOYD #Diabetes #OnceWeeklyBasalInsulin #ReadToday!

How to Reduce Alprazolam Safely! After long-term treatment, rapidly reducing the dose or stopping alprazolam abruptly can trigger severe withdrawal symptoms, which can be dangerous. To avoid these risks, it is crucial to taper off alprazolam gradually. Typically, the dose should be reduced by 0.5 mg every three days. For those on alprazolam for a long time, switching to a longer-acting medication like clonazepam or diazepam before tapering can help minimize withdrawal effects and ensure safety. #pharmacy #medicationsafety #patientcare #pharmd